Gene: RIMS2

9699
OBOE|RAB3IP3|RIM2
regulating synaptic membrane exocytosis 2
protein-coding
8q22.3
Ensembl:ENSG00000176406 MIM:606630 Vega:OTTHUMG00000162097 UniprotKB:Q9UQ26
NG_053027.1
SNP Mapped
1   ANCO-SNPs
CD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
4.696e-1 (AD)  8.865e-2 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs75686122chr8:103561561 (GRCh38.p7)C>A / C>Tcocaine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
RIMS10.866
KIF1B0.851
RB1CC10.845
NNT0.825
KIF5C0.806
IDS0.795
APC0.791
AKAP60.777
IARS20.773
EPS150.768

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.583
OR4F29-0.56
PRRX2-0.325
GSC-0.324
S100A3-0.316
EGFLAM-0.304
APOL4-0.3
TSLP-0.293
IRX3-0.293
FLT3LG-0.293

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in decreased expression of RIMS2 mRNA"18648102
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIMS2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIMS2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIMS2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIMS2 mRNA"27188386
D020106AcrylamideAcrylamide results in decreased expression of RIMS2 mRNA28959563
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of RIMS2 gene27153756
D000643Ammonium ChlorideAmmonium Chloride affects the expression of RIMS2 mRNA16483693
C006632arsenic trioxidearsenic trioxide results in decreased expression of RIMS2 mRNA26705709
D001280AtrazineAtrazine results in decreased expression of RIMS2 mRNA22378314
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of RIMS2 mRNA22228805
C006780bisphenol Abisphenol A affects the expression of RIMS2 mRNA25181051
C013418bromfenacoumbromfenacoum results in decreased expression of RIMS2 protein28903499
D002110CaffeineCaffeine results in decreased expression of RIMS2 mRNA20864626
D003474CurcuminCurcumin results in decreased expression of RIMS2 mRNA17999991
D004052DiethylnitrosamineDiethylnitrosamine results in increased expression of RIMS2 mRNA24535843
C065180fluvastatin[zoledronic acid co-treated with fluvastatin] results in increased expression of RIMS2 mRNA16996129
C011890kojic acidkojic acid results in decreased expression of RIMS2 mRNA16595896
C018091maduramicinmaduramicin results in decreased expression of RIMS2 mRNA29128925
D058185Magnetite Nanoparticles[Succimer binds to Magnetite Nanoparticles] which results in increased expression of RIMS2 mRNA21641980
D058185Magnetite Nanoparticles[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of RIMS2 mRNA26378955
D008694Methamphetamine[Methamphetamine co-treated with SCH 23390] results in increased expression of RIMS2 mRNA19564919
D008694MethamphetamineMethamphetamine results in increased expression of RIMS2 mRNA19564919
D008727MethotrexateMethotrexate affects the expression of RIMS2 mRNA18502557
C013598methoxyacetic acidmethoxyacetic acid results in decreased expression of RIMS2 mRNA20864626
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of RIMS2 mRNA20864626
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of RIMS2 mRNA"20188158
C028577monobutyl phthalatemonobutyl phthalate results in decreased expression of RIMS2 mRNA20864626
D009532NickelNickel results in decreased expression of RIMS2 mRNA24768652
C044387N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine"N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of RIMS2 mRNA"12756304
C006253pirinixic acidpirinixic acid results in increased expression of RIMS2 mRNA18301758|2081375
C089730rosiglitazonerosiglitazone results in decreased expression of RIMS2 mRNA25572481
C534628SCH 23390[Methamphetamine co-treated with SCH 23390] results in increased expression of RIMS2 mRNA19564919
C534628SCH 23390SCH 23390 results in increased expression of RIMS2 mRNA19564919
C017947sodium arsenitesodium arsenite affects the methylation of RIMS2 gene28589171
D004113Succimer[Succimer binds to Magnetite Nanoparticles] which results in increased expression of RIMS2 mRNA21641980
D004113Succimer[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of RIMS2 mRNA26378955
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIMS2 mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of RIMS2 mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RIMS2 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of RIMS2 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of RIMS2 mRNA23179753|2438349
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of RIMS2 gene25560391
C025643vinclozolinvinclozolin affects the expression of RIMS2 mRNA19015723
D019287Zinc SulfateZinc Sulfate results in decreased expression of RIMS2 mRNA12756304
C088658zoledronic acid[zoledronic acid co-treated with fluvastatin] results in increased expression of RIMS2 mRNA16996129

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI17474147  
GO:0017137Rab GTPase binding-IBA21873635  
GO:0017137Rab GTPase binding-IEA-  
GO:0044325ion channel binding-IBA21873635  
GO:0044325ion channel binding-ISS-  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006886intracellular protein transport-IEA-  
GO:0010628positive regulation of gene expression-ISS-  
GO:0017156calcium ion regulated exocytosis-ISS-  
GO:0017157regulation of exocytosis-ISS-  
GO:0019933cAMP-mediated signaling-ISS-  
GO:0030073insulin secretion-ISS-  
GO:0042391regulation of membrane potential-IBA21873635  
GO:0042391regulation of membrane potential-ISS-  
GO:0048167regulation of synaptic plasticity-IBA21873635  
GO:0048791calcium ion-regulated exocytosis of neurotransmitter-IBA21873635  
GO:0048791calcium ion-regulated exocytosis of neurotransmitter-ISS-  
GO:0050806positive regulation of synaptic transmission-IBA21873635  
GO:0061669spontaneous neurotransmitter secretion-ISS-  
GO:0097151positive regulation of inhibitory postsynaptic potential-ISS-  
GO:1903861positive regulation of dendrite extension-IDA23999003  
GO:2000300regulation of synaptic vesicle exocytosis-IBA21873635  
GO:2000463positive regulation of excitatory postsynaptic potential-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005622intracellular-IEA-  
GO:0030054cell junction-IEA-  
GO:0042734presynaptic membrane-IBA21873635  
GO:0042734presynaptic membrane-IEA-  
GO:0045202synapse-IBA21873635  
GO:0048786presynaptic active zone-TAS15217342  
GO:0048788cytoskeleton of presynaptic active zone-IBA21873635  
GO:0070062extracellular exosome-HDA18570454  
GO:0098831presynaptic active zone cytoplasmic component-IBA21873635  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal